Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs)

Fecha de publicación: Fecha Ahead of Print:

Autores organización

Autores

  • Ávila V
  • Arrieta O

Grupos de investigación

Resumen

[No abstract available]

Datos de la publicación

ISSN/ISSNe:
2666-2345, 2590-017X

Journal Of Immunotherapy And Precision Oncology  Innovative Healthcare Institute

Tipo:
Letter
Páginas:
185-186
Enlace a otro recurso:
www.scopus.com

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • afatinib; epidermal growth factor receptor; erlotinib; gefitinib; immune checkpoint inhibitor; osimertinib; cancer mortality; cancer therapy; cost; cost effectiveness analysis; EGFR gene; financial cost; gene; gene mutation; health care cost; health care system; human; immunotherapy; Letter; low income country; lung adenocarcinoma; middle income country; non small cell lung cancer; overall survival; probability; public health; quality adjusted life year; smoke; tumor mutational burden; wood smoke exposure

Campos de estudio

Citar la publicación

Compartir la publicación